DK1230932T3 - Anvendelse af antistoffer til vaccinering mod cancer - Google Patents
Anvendelse af antistoffer til vaccinering mod cancerInfo
- Publication number
- DK1230932T3 DK1230932T3 DK02005394T DK02005394T DK1230932T3 DK 1230932 T3 DK1230932 T3 DK 1230932T3 DK 02005394 T DK02005394 T DK 02005394T DK 02005394 T DK02005394 T DK 02005394T DK 1230932 T3 DK1230932 T3 DK 1230932T3
- Authority
- DK
- Denmark
- Prior art keywords
- against cancer
- antibodies
- vaccination against
- prophylactically
- medicament
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 238000002255 vaccination Methods 0.000 title 1
- 101710181478 Envelope glycoprotein GP350 Proteins 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH5199 | 1999-01-13 | ||
| EP00906191A EP1140168B1 (de) | 1999-01-13 | 2000-01-12 | Verwendung von antikörpern zur vakzinierung gegen krebs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1230932T3 true DK1230932T3 (da) | 2005-04-25 |
Family
ID=4178206
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK02005394T DK1230932T3 (da) | 1999-01-13 | 2000-01-12 | Anvendelse af antistoffer til vaccinering mod cancer |
| DK00906191T DK1140168T3 (da) | 1999-01-13 | 2000-01-12 | Anvendelse af antistoffer til vaccination mod cancer |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK00906191T DK1140168T3 (da) | 1999-01-13 | 2000-01-12 | Anvendelse af antistoffer til vaccination mod cancer |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US7691372B2 (enExample) |
| EP (2) | EP1230932B1 (enExample) |
| JP (1) | JP4774551B2 (enExample) |
| KR (1) | KR100771752B1 (enExample) |
| CN (1) | CN1188169C (enExample) |
| AT (2) | ATE286745T1 (enExample) |
| AU (1) | AU768515B2 (enExample) |
| CA (1) | CA2360382C (enExample) |
| CZ (1) | CZ302801B6 (enExample) |
| DE (2) | DE50000243D1 (enExample) |
| DK (2) | DK1230932T3 (enExample) |
| EE (1) | EE05474B1 (enExample) |
| ES (2) | ES2177509T3 (enExample) |
| HK (1) | HK1044487B (enExample) |
| HR (1) | HRP20010526A2 (enExample) |
| HU (1) | HU226150B1 (enExample) |
| ID (1) | ID30223A (enExample) |
| IL (2) | IL144265A0 (enExample) |
| IS (1) | IS5998A (enExample) |
| MX (1) | MXPA01007148A (enExample) |
| NO (1) | NO329917B1 (enExample) |
| NZ (1) | NZ512722A (enExample) |
| PL (1) | PL201533B1 (enExample) |
| PT (2) | PT1230932E (enExample) |
| SI (2) | SI1230932T1 (enExample) |
| SK (1) | SK286627B6 (enExample) |
| TR (1) | TR200102034T2 (enExample) |
| WO (1) | WO2000041722A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1230932B1 (de) * | 1999-01-13 | 2005-01-12 | Igeneon Krebs-Immuntherapie Forschungs- und Entwicklungs-AG | Verwendung von Antikörpern zur Vakzinierung gegen Krebs |
| AT410172B (de) * | 2000-03-21 | 2003-02-25 | Igeneon Gmbh | Verfahren zur herstellung einer vakzineformulierung |
| US20070122406A1 (en) | 2005-07-08 | 2007-05-31 | Xencor, Inc. | Optimized proteins that target Ep-CAM |
| AT502293B1 (de) * | 2002-05-15 | 2008-03-15 | Igeneon Krebs Immuntherapie | Immunogener, monoklonaler antikörper |
| AT500647A1 (de) * | 2002-05-21 | 2006-02-15 | Igeneon Krebs Immuntherapie | Verwendung eines impfstoffes |
| AT500650B1 (de) | 2003-04-17 | 2009-11-15 | Altropus Gmbh | Immunogener rekombinanter antikörper |
| AT500651B9 (de) * | 2003-05-27 | 2010-04-15 | Altropus Gmbh | Aktiv immunisierender antikörper |
| WO2006005367A1 (en) | 2004-07-14 | 2006-01-19 | Igeneon Krebs-Immuntherapie Forschungs-Und Entwicklungs-Ag | N-glycosylated antibody |
| EP1618890B1 (en) * | 2004-07-20 | 2010-10-06 | Altropus Gmbh | Use of antibodies in a very low dose for the vaccination against cancer |
| CN101355928B (zh) * | 2005-04-26 | 2013-05-22 | 卫材R&D管理株式会社 | 用于癌症免疫疗法的组合物和方法 |
| EP1762575A1 (en) * | 2005-09-12 | 2007-03-14 | Ganymed Pharmaceuticals AG | Identification of tumor-associated antigens for diagnosis and therapy |
| AT504231A1 (de) | 2006-10-03 | 2008-04-15 | Hans Dr Loibner | Prädiktive parameter |
| EP2217253B1 (en) | 2007-12-07 | 2011-06-29 | N.V. Nutricia | Bifidobacterium for dust mite allergy |
| MX2011007049A (es) | 2009-02-24 | 2011-08-03 | Esbatech Alcon Biomed Res Unit | Metodos para identificar inmunoligadores de los antegenos de la superficie celular. |
| US8887373B2 (en) | 2012-02-24 | 2014-11-18 | Covidien Lp | Vessel sealing instrument with reduced thermal spread and method of manufacture therefor |
| US20140276968A1 (en) * | 2013-03-14 | 2014-09-18 | Ethicon, Inc. | Applicator systems for surgical fasteners |
| US10196458B2 (en) * | 2013-07-26 | 2019-02-05 | The Regents Of The University Of California | Anti-immunoglobulin E antibodies and methods of using thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1341281C (en) * | 1986-07-09 | 2001-08-07 | Hubert J.P. Schoemaker | Immunotherapy of tumor with monoclonal antibody against the 17-1a antigen |
| US5270202A (en) | 1989-11-03 | 1993-12-14 | Syamal Raychaudhuri | Anti-idiotypic antibodies to human melanoma-associated proteoglycan antigen |
| US5965132A (en) * | 1992-03-05 | 1999-10-12 | Board Of Regents, The University Of Texas System | Methods and compositions for targeting the vasculature of solid tumors |
| US5798100A (en) * | 1994-07-06 | 1998-08-25 | Immunomedics, Inc. | Multi-stage cascade boosting vaccine |
| WO1997005597A1 (en) * | 1995-07-31 | 1997-02-13 | Litton Systems Canada Limited | Flat panel pixel array incorporating photoconductive switches |
| EP0857176A1 (en) * | 1995-10-25 | 1998-08-12 | Centocor B.V. | HUMAN EPITHELIAL ANTIGEN Ep-CAM DERIVED PEPTIDES AND THEIR USE |
| US6235280B1 (en) | 1996-04-12 | 2001-05-22 | Malaya Chatterjee | Methods of delaying development of CEA-associated tumors using anti-idiotype antibody 3H1 |
| IL121041A0 (en) * | 1997-06-09 | 1997-11-20 | Yeda Res & Dev | Immunogenic compositions for induction of anti-tumor immunity |
| US6274143B1 (en) * | 1997-06-13 | 2001-08-14 | Malaya Chatterjee | Methods of delaying development of HMFG-associated tumors using anti-idiotype antibody 11D10 |
| ATE480566T1 (de) * | 1998-06-15 | 2010-09-15 | Quest Pharmatech Inc | Immuntherapeutische zusammensetzung und verfahren zur behandlung von prostatakrebs |
| EP1230932B1 (de) * | 1999-01-13 | 2005-01-12 | Igeneon Krebs-Immuntherapie Forschungs- und Entwicklungs-AG | Verwendung von Antikörpern zur Vakzinierung gegen Krebs |
| AU2001261371A1 (en) | 2000-05-16 | 2001-11-26 | New York University | Anti-idiotypic antibody against fimh adhesin of uropathogenic type i-fimbriated escherichia coli, compositions containing same and method for using same |
-
2000
- 2000-01-12 EP EP02005394A patent/EP1230932B1/de not_active Expired - Lifetime
- 2000-01-12 WO PCT/EP2000/000174 patent/WO2000041722A1/de not_active Ceased
- 2000-01-12 HK HK02106215.4A patent/HK1044487B/zh not_active IP Right Cessation
- 2000-01-12 PT PT02005394T patent/PT1230932E/pt unknown
- 2000-01-12 CZ CZ20012581A patent/CZ302801B6/cs not_active IP Right Cessation
- 2000-01-12 DE DE50000243T patent/DE50000243D1/de not_active Expired - Lifetime
- 2000-01-12 PT PT00906191T patent/PT1140168E/pt unknown
- 2000-01-12 AU AU27964/00A patent/AU768515B2/en not_active Ceased
- 2000-01-12 ES ES00906191T patent/ES2177509T3/es not_active Expired - Lifetime
- 2000-01-12 HR HR20010526A patent/HRP20010526A2/hr not_active Application Discontinuation
- 2000-01-12 SI SI200030594T patent/SI1230932T1/xx unknown
- 2000-01-12 ID IDW00200101396A patent/ID30223A/id unknown
- 2000-01-12 CN CNB008027641A patent/CN1188169C/zh not_active Expired - Fee Related
- 2000-01-12 SI SI200030015T patent/SI1140168T1/xx unknown
- 2000-01-12 TR TR2001/02034T patent/TR200102034T2/xx unknown
- 2000-01-12 IL IL14426500A patent/IL144265A0/xx active IP Right Grant
- 2000-01-12 ES ES02005394T patent/ES2236375T3/es not_active Expired - Lifetime
- 2000-01-12 PL PL364747A patent/PL201533B1/pl not_active IP Right Cessation
- 2000-01-12 AT AT02005394T patent/ATE286745T1/de active
- 2000-01-12 NZ NZ512722A patent/NZ512722A/en not_active IP Right Cessation
- 2000-01-12 MX MXPA01007148A patent/MXPA01007148A/es not_active IP Right Cessation
- 2000-01-12 SK SK964-2001A patent/SK286627B6/sk not_active IP Right Cessation
- 2000-01-12 KR KR1020017008697A patent/KR100771752B1/ko not_active Expired - Fee Related
- 2000-01-12 CA CA2360382A patent/CA2360382C/en not_active Expired - Fee Related
- 2000-01-12 EE EEP200100366A patent/EE05474B1/xx not_active IP Right Cessation
- 2000-01-12 DK DK02005394T patent/DK1230932T3/da active
- 2000-01-12 JP JP2000593332A patent/JP4774551B2/ja not_active Expired - Fee Related
- 2000-01-12 HU HU0200527A patent/HU226150B1/hu not_active IP Right Cessation
- 2000-01-12 DE DE50009240T patent/DE50009240D1/de not_active Expired - Lifetime
- 2000-01-12 AT AT00906191T patent/ATE219687T1/de active
- 2000-01-12 EP EP00906191A patent/EP1140168B1/de not_active Expired - Lifetime
- 2000-01-12 DK DK00906191T patent/DK1140168T3/da active
-
2001
- 2001-06-21 NO NO20013093A patent/NO329917B1/no not_active IP Right Cessation
- 2001-07-10 IS IS5998A patent/IS5998A/is unknown
- 2001-07-11 IL IL144265A patent/IL144265A/en not_active IP Right Cessation
-
2006
- 2006-10-10 US US11/548,269 patent/US7691372B2/en not_active Expired - Fee Related
-
2009
- 2009-09-18 US US12/562,886 patent/US20100233178A1/en not_active Abandoned
-
2011
- 2011-08-12 US US13/209,285 patent/US8444974B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1140168T3 (da) | Anvendelse af antistoffer til vaccination mod cancer | |
| DE60202877D1 (de) | Gezieltes antikörper-verfahren | |
| TR200001253T2 (tr) | Tümöre özel antijenler | |
| CR8698A (es) | Anticuerpos monoclonales al factor de crecimiento de hepatocito | |
| FR12C0004I2 (fr) | Anticorps contre l'antigene ctla-4 humain et utilisation | |
| ATE542829T1 (de) | Impfstoff | |
| BRPI0412245A (pt) | anticorpos de rg1 e usos destes | |
| IS7133A (is) | Afleiða beta-amyloid - T-frumu-mótefnavísisbóluefni | |
| CY1110322T1 (el) | Αναστολεις της her3 δραστικοτητας | |
| CY1113243T1 (el) | Μεθοδοι θεραπειας με χρηση αντισωματων cτlα-4 | |
| AR016821A1 (es) | Procedimiento mejorado para la obtencion de precursores de insulina con puentes de cistina correctamente unidos | |
| BRPI0418317A (pt) | vacina de aumento de crescimento à base de epitopo de neutralização | |
| DK1476468T3 (da) | Fab-fragmenter af humant monoklonalt antistof rettet mod HCV E2-glycoprotein og med in vitro-neutraliserende aktivitet | |
| DK1167389T3 (da) | Antistoffer mod SEMP1-proteinet, fremgangsmåde til fremstilling heraf samt anvendelse deraf | |
| ATE370745T1 (de) | Verbesserte polysaccharid- und glykokonjugat- vakzine | |
| DE50214797D1 (de) | Rezeptor, dessen verwendung sowie mausantikörper | |
| DE60233936D1 (de) | Therapeutische Zusammenseztungen zur Toleranzinduktion | |
| ATE483473T1 (de) | Verwendung von antikörpern in einer sehr geringen dosis zur impfung gegen krebs | |
| AR027540A1 (es) | Utilizacion de la proteina mic3 de toxoplasma gondii o de uno de sus derivados como agente inmunogeno o como antigeno de vacunacion | |
| CY1114280T1 (el) | Αντισωματα ανταγωνιστων των κυτοκινων θηλαστικων ή οι υποδοχεις τους για την αγωγη της αλλεργιας | |
| BR0007814A (pt) | Uso de anticorpos para a vacinação contra câncer | |
| CY1114835T1 (el) | Πληρη ανθρωπινα αντισωματα εναντι ανθρωπινου 4-1ββ (cd137) | |
| UY26673A1 (es) | Proceso de producción de antígeno recombinante para inmunodiagnóstico de hidatidosis |